Abstract:Background The RNA-binding protein Musashi-2 (MSI2) has been implicated in the tumorigenesis and tumor progression of some human cancers. MSI2 has also been reported to suppress tumor epithelial-to-mesenchymal transition (EMT) progression in breast cancer, and low MSI2 expression is associated with poor outcomes for breast cancer patients; however, the underlying mechanisms have not been fully investigated. This study investigated the expression and phenotypic functions of two major alternatively spliced MSI2 isoforms (MSI2a and MSI2b) and the potential molecular mechanisms involved in triple-negative breast cancer (TNBC) progression. Methods The Illumina sequencing platform was used to analyze the mRNA transcriptomes of TNBC and normal tissues, while quantitative reverse transcription-polymerase chain reaction and immunohistochemistry validated MSI2 isoform expression in breast cancer tissues. The effects of MSI2a and MSI2b on TNBC cells were assayed in vitro and in vivo. RNA immunoprecipitation (RIP) and RNA sequencing were performed to identify the potential mRNA targets of MSI2a, and RIP and luciferase analyses were used to confirm the mRNA targets of MSI2. Results MSI2 expression in TNBC tissues was significantly downregulated compared to that in normal tissues. In TNBC, MSI2a expression was associated with poor overall survival of patients. MSI2a overexpression in vitro and in vivo inhibited TNBC cell invasion as well as extracellular signal-regulated kinase 1/2 (ERK1/2) activity. However, MSI2b overexpression had no significant effects on TNBC cell migration. Mechanistically, MSI2a expression promoted TP53INP1 mRNA stability by its interaction with the 3′-untranslated region of TP53INP1 mRNA. Furthermore, TP53INP1 knockdown reversed MSI2a-induced suppression of TNBC cell invasion, whereas ectopic expression of TP53INP1 and inhibition of ERK1/2 activity blocked MSI2 knockdown-induced TNBC cell invasion. Conclusions The current study demonstrated that MSI2a is the predominant functional isoform of MSI2 proteins in TNBC, that its downregulation is associated with TNBC progression and poor prognosis and that MSI2a expression inhibited TNBC invasion by stabilizing TP53INP1 mRNA and inhibiting ERK1/2 activity. Overall, our study provides new insights into the isoform-specific roles of MSI2a and MSI2b in the tumor progression of TNBC, allowing for novel therapeutic strategies to be developed for TNBC.

Differential expression of MAGI2-antisense RNA 3 in cancers of the breast.

RNA-sequencing and Microarray Data Mining Revealing: the Aberrantly Expressed Mrnas Were Related with a Poor Outcome in the Triple Negative Breast Cancer Patients

LncRNA MAGI2-AS3-Encoded Polypeptide Restrains the Proliferation and Migration of Breast Cancer Cells

Rna-Sequence Analysis Reveals Differentially Expressed Genes (degs) in Patients Exhibiting Different Risks of Tumor Metastasis

Differential expression of membrane metallo-endopeptidase, MME, in cancers of the breast.

Differential expression of MFAP4 in cancers of the breast.

MAGI2‐AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2

Differential expression of transformer 2 alpha homolog in cancers of the breast.

Roles of lncRNA MAGI2-AS3 in human cancers

Differential expression of CDO1 in cancers of the breast.

MAGI1 Prevents Senescence and Promotes the DNA Damage Response in ER+ Breast Cancer

MEX3D is a differentially expressed gene in human metastatic breast cancer, in the brain and in the lymph nodes.

Identifying Breast Cancer Risk Loci by Global Differential Allele-Specific Expression (dase) Analysis in Mammary Epithelial Transcriptome

MAGI2 antisense RNA 3 (MAGI2-AS3) knockdown contributes to prostate cancer by downregulating proline-rich membrane anchor 1 (PRIMA1) via miR-142-3p

RNA-binding Protein MSI2 Isoforms Expression and Regulation in Progression of Triple-Negative Breast Cancer

Long non-coding RNA MAGI2 -AS3 inactivates STAT3 pathway to inhibit prostate cancer cell proliferation via acting as a microRNA-424-5p sponge

LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis

The Knockdown of MAGI2-AS3 Inhibits Drug Resistance in Acute Myeloid Leukemia by Up Regulating Mir-155

Differential expression of ATP binding cassette subfamily A member 6 in cancers of the breast.

Increased expression of mdig predicts poorer survival of the breast cancer patients

Differential MYC and PROM1 mRNA isoform expression in breast invasive carcinoma as biomarkers for subtyping and prognosis